Tags

Type your tag names separated by a space and hit enter

Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Cardiorenal Med. 2020; 10(5):277-287.CM

Abstract

BACKGROUND

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently emerged in Wuhan, Hubei-China, as responsible for the coronavirus disease 2019 (COVID-19) and then spread rapidly worldwide. While most individuals remain asymptomatic or develop only mild symptoms, approximately 5% develop severe forms of COVID-19 characterized by acute respiratory distress syndrome (ARDS) and multiple-organ failure (MOF) that usually require intensive-care support and often yield a poor prognosis.

SUMMARY

The pathophysiology of COVID-19 is far from being completely understood, and the lack of effective treatments leads to a sense of urgency to develop new therapeutic strategies based on pathophysiological assumptions. The exaggerated cytokine release in response to viral infection, a condition known as cytokine release syndrome (CRS) or cytokine storm, is emerging as the mechanism leading to ARDS and MOF in COVID-19, thus endorsing the hypothesis that properly timed anti-inflammatory therapeutic strategies could improve patients' clinical outcomes and prognosis. Key Messages: The objective of this article is to explore and comment on the potential role of the promising immunomodulatory therapies using pharmacological and nonpharmacological approaches to overcome the dysregulated proinflammatory response in COVID-19.

Authors+Show Affiliations

Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy.Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy.Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy.Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy.Department of Medicine, University of Padova, Padua, Italy. Department of Nephrology, Dialysis and Kidney Transplant, International Renal Research Institute, San Bortolo Hospital, Vicenza, Italy.Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, Louisiana, USA.Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy. Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, Italy. Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, nadia.aspromonte@policlinicogemelli.it.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32599589

Citation

Iannaccone, Giulia, et al. "Weathering the Cytokine Storm in COVID-19: Therapeutic Implications." Cardiorenal Medicine, vol. 10, no. 5, 2020, pp. 277-287.
Iannaccone G, Scacciavillani R, Del Buono MG, et al. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. Cardiorenal Med. 2020;10(5):277-287.
Iannaccone, G., Scacciavillani, R., Del Buono, M. G., Camilli, M., Ronco, C., Lavie, C. J., Abbate, A., Crea, F., Massetti, M., & Aspromonte, N. (2020). Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. Cardiorenal Medicine, 10(5), 277-287. https://doi.org/10.1159/000509483
Iannaccone G, et al. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. Cardiorenal Med. 2020;10(5):277-287. PubMed PMID: 32599589.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. AU - Iannaccone,Giulia, AU - Scacciavillani,Roberto, AU - Del Buono,Marco Giuseppe, AU - Camilli,Massimiliano, AU - Ronco,Claudio, AU - Lavie,Carl J, AU - Abbate,Antonio, AU - Crea,Filippo, AU - Massetti,Massimo, AU - Aspromonte,Nadia, Y1 - 2020/06/29/ PY - 2020/05/14/received PY - 2020/06/12/accepted PY - 2020/7/1/pubmed PY - 2020/9/25/medline PY - 2020/6/30/entrez KW - COVID-19 KW - Cytokine storm KW - Therapy SP - 277 EP - 287 JF - Cardiorenal medicine JO - Cardiorenal Med VL - 10 IS - 5 N2 - BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently emerged in Wuhan, Hubei-China, as responsible for the coronavirus disease 2019 (COVID-19) and then spread rapidly worldwide. While most individuals remain asymptomatic or develop only mild symptoms, approximately 5% develop severe forms of COVID-19 characterized by acute respiratory distress syndrome (ARDS) and multiple-organ failure (MOF) that usually require intensive-care support and often yield a poor prognosis. SUMMARY: The pathophysiology of COVID-19 is far from being completely understood, and the lack of effective treatments leads to a sense of urgency to develop new therapeutic strategies based on pathophysiological assumptions. The exaggerated cytokine release in response to viral infection, a condition known as cytokine release syndrome (CRS) or cytokine storm, is emerging as the mechanism leading to ARDS and MOF in COVID-19, thus endorsing the hypothesis that properly timed anti-inflammatory therapeutic strategies could improve patients' clinical outcomes and prognosis. Key Messages: The objective of this article is to explore and comment on the potential role of the promising immunomodulatory therapies using pharmacological and nonpharmacological approaches to overcome the dysregulated proinflammatory response in COVID-19. SN - 1664-5502 UR - https://www.unboundmedicine.com/medline/citation/32599589/Weathering_the_Cytokine_Storm_in_COVID_19:_Therapeutic_Implications_ DB - PRIME DP - Unbound Medicine ER -